Avalo Therapeutics (Cerecor)

We are a clinical stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We have a portfolio of clinical and preclinical compounds that we believe are best in class and where human proof of concept has been established for the compound or the target. We are currently pursuing regulatory approval of three product candidates: CERC-301 (major depressive disorder), CERC-501 (substance use disorders) and CERC-406 (residual cognitive impairment).